China
· Delayed Price · Currency is CNY Jiangsu Hengrui Medicine Statistics
Total Valuation
Jiangsu Hengrui Medicine has a market cap or net worth of CNY 282.32 billion. The enterprise value is 259.69 billion.
| Market Cap | 282.32B |
| Enterprise Value | 259.69B |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | Jul 12, 2024 |
Share Statistics
Jiangsu Hengrui Medicine has 6.36 billion shares outstanding. The number of shares has decreased by -1.56% in one year.
| Shares Outstanding | 6.36B |
| Shares Change (YoY) | -1.56% |
| Shares Change (QoQ) | -5.02% |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 20.58% |
| Float | 3.41B |
Valuation Ratios
The trailing PE ratio is 51.54 and the forward PE ratio is 48.07. Jiangsu Hengrui Medicine's PEG ratio is 4.02.
| PE Ratio | 51.54 |
| Forward PE | 48.07 |
| PS Ratio | 11.07 |
| PB Ratio | 6.45 |
| P/FCF Ratio | 44.54 |
| PEG Ratio | 4.02 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 42.83, with an EV/FCF ratio of 40.97.
| EV / Earnings | 47.86 |
| EV / Sales | 10.28 |
| EV / EBITDA | 42.83 |
| EV / EBIT | 48.96 |
| EV / FCF | 40.97 |
Financial Position
The company has a current ratio of 7.23, with a Debt / Equity ratio of 0.22.
| Current Ratio | 7.23 |
| Quick Ratio | 6.37 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.01 |
| Interest Coverage | 958.99 |
Financial Efficiency
Return on equity (ROE) is 13.11% and return on invested capital (ROIC) is 8.01%.
| Return on Equity (ROE) | 13.11% |
| Return on Assets (ROA) | 7.36% |
| Return on Capital (ROIC) | 8.01% |
| Revenue Per Employee | 1.29M |
| Profits Per Employee | 276,677 |
| Employee Count | 19,611 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.57 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.01% in the last 52 weeks. The beta is 0.23, so Jiangsu Hengrui Medicine's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +9.01% |
| 50-Day Moving Average | 41.96 |
| 200-Day Moving Average | 43.25 |
| Relative Strength Index (RSI) | 58.89 |
| Average Volume (20 Days) | 24,336,730 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Jiangsu Hengrui Medicine had revenue of CNY 25.25 billion and earned 5.43 billion in profits. Earnings per share was 0.86.
| Revenue | 25.25B |
| Gross Profit | 21.60B |
| Operating Income | 5.30B |
| Pretax Income | 5.91B |
| Net Income | 5.43B |
| EBITDA | 6.01B |
| EBIT | 5.30B |
| Earnings Per Share (EPS) | 0.86 |
Balance Sheet
The company has 23.29 billion in cash and 95.02 million in debt, giving a net cash position of 23.19 billion or 3.65 per share.
| Cash & Cash Equivalents | 23.29B |
| Total Debt | 95.02M |
| Net Cash | 23.19B |
| Net Cash Per Share | 3.65 |
| Equity (Book Value) | 43.19B |
| Book Value Per Share | 6.88 |
| Working Capital | 29.97B |
Cash Flow
In the last 12 months, operating cash flow was 7.80 billion and capital expenditures -1.46 billion, giving a free cash flow of 6.34 billion.
| Operating Cash Flow | 7.80B |
| Capital Expenditures | -1.46B |
| Free Cash Flow | 6.34B |
| FCF Per Share | 1.00 |
Margins
Gross margin is 85.54%, with operating and profit margins of 21.00% and 21.49%.
| Gross Margin | 85.54% |
| Operating Margin | 21.00% |
| Pretax Margin | 23.39% |
| Profit Margin | 21.49% |
| EBITDA Margin | 23.79% |
| EBIT Margin | 21.00% |
| FCF Margin | 25.10% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 0.45%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 0.45% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.73% |
| Buyback Yield | 1.56% |
| Shareholder Yield | 2.01% |
| Earnings Yield | 1.94% |
| FCF Yield | 2.24% |
Stock Splits
The last stock split was on June 10, 2021. It was a forward split with a ratio of 1.2.
| Last Split Date | Jun 10, 2021 |
| Split Type | Forward |
| Split Ratio | 1.2 |